Purpose
This study aimed to examine the causes of death in Korean patients who underwent radical prostatectomy for prostate cancer and investigate the relationship between comorbidity and mortality.
Materials and Methods
We conducted a retrospective multicenter cohort study including 4,064 consecutive patients who had prostate cancer and underwent radical prostatectomy between January 1998 and June 2013. The primary endpoint of this study was all-cause mortality, and the secondary endpoints were cancer-specific mortality (CSM) and other-cause mortality (OCM). Charlson comorbidity index (CCI) was calculated to assess the comorbidities of each patient.
Results
Of 4,064 patients, 446 (11.0%) died during follow-up. The cause of death was prostate cancer in 132 patients (29.6%), other cancers in 121 patients (27.1%), and vascular disease in 57 patients (12.8%) in our cohort. The overall 10-year CSM rate was lower than the OCM rate (4.6% vs. 10.5%). The 10-year CSM rate was lower than the OCM rate in low- to intermediate-risk group patients (1.2% vs. 10.6%), whereas they were similar in high-risk group patients (11.8% vs. 10.1%). In the multivariable analysis, CCI was independently associated with all-cause mortality after radical prostatectomy, regardless of age and pathologic features.
Conclusion
Death from prostate cancer was rare in Korean men who underwent radical prostatectomy. Clinicians should be aware of the possibility of overtreatment of low-risk prostate cancer in men with significant comorbidity. Our findings may help to facilitate counseling and plan management in this patient group.
Purpose
Previous western studies have found Caucasians with skin cancer, either melanoma or nonmelanoma skin cancer (NMSC), have an elevated risk of second primary cancer. Our objective was to assess the risk of second primary cancer in Taiwanese with NMSC.
Materials and Methods
By using data from Taiwan’s National Health Insurance Research Database, we conducted a population-based cohort study to assess the risk of incident second primary cancer in Taiwanese affected by NMSC.
Results
We identified 505 subjects with NMSC and 2,020 matched controls. After adjustment for potential confounders including age, sex, urbanization, and Charlson Comorbidity Index, people who had NMSC had a 1.43-fold (95% confidence interval [CI], 1.05 to 1.96) risk for the development of second primary cancer as comparedwith control group. Menwith NMSC had a 2.99-fold (95% CI, 1.00 to 9.10) risk for second primary cancer involving the lip, oral cavity, and pharynx and a 3.51-fold (95% CI, 1.21 to 10.17) risk for second primary cancer involving the genitourinary organs when compared to the control group. By contrast, women with NMSC did not have an increased risk of second primary cancer.
Conclusion
This study revealed Asians with NMSC have an increased risk of second primary cancer. Our findings can be a useful reference for health care for people diagnosed with NMSC.
Citations
Citations to this article as recorded by
Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan Leukemia Research.2024; 147: 107610. CrossRef
Non‐melanoma skin cancer as a clinical marker for internal malignancies: a nationwide population‐based cohort study S.J. Yun, J.M. Bae, H. Kim, B.C. Park, J.S. Kim, S.H. Seo, H.H. Ahn, D.Y. Lee, Y.C. Kim, H.J. Park, K.Y. Chung Journal of the European Academy of Dermatology and Venereology.2020; 34(4): 746. CrossRef
Purpose
Previous studies reported an association between an increased risk of tongue cancer and radiation treatment for nasopharyngeal carcinoma (NPC). This study compared the clinicopathologic characteristics and outcomes of tongue squamous cell carcinoma (TSCC) in patients with and without a history of radiotherapy for NPC.
Materials and Methods
From 1965 to 2009, a total of 73 patients were diagnosed with TSCC with a history of radiotherapy for NPC. The patients were matched in a 1:3 ratio with patients with sporadic TSCC according to age, sex, and year of the TSCC diagnosis. The primary endpoint was the overall survival.
Results
The median interval from NPC to TSCC was 82 months. The NPC survivors were more likely to be diagnosed with a more advanced T classification, less likely to have lymph node involvement, and more likely to have the tumor located in the dorsum of the tongue than sporadic TSCC. Regarding the histologic characteristics, the NPC survivors were more likely to have a weak lymphocytic host response, low tumor budding, and low risk of a worse pattern of invasion. The sporadic TSCC patients had a better overall survival (hazard ratio, 0.690; p=0.033) than the NPC survivors. In competing risks analysis, the cumulative incidence functions for the competing event (documented non-tongue cancer death) were significantly higher in the NPC survivors (Gray’s test, p=0.001).
Conclusion
TSCC patients with a history of radiotherapy for NPC appear to have particular clinicopathologic features, a poorer survival, and are more likely to die from non-tongue cancer causes than those with sporadic TSCC.
Citations
Citations to this article as recorded by
Radiotherapy upregulated immune checkpoints contribute to the development of second primary OSCC Li Wang, Siyu Wang, Jiayu Zhang, Jianmin Peng, Bin Cheng, Huan Li, Qinchao Hu Oral Diseases.2024; 30(4): 2188. CrossRef
Impact of histopathological parameters in prognosis of oral squamous cell carcinoma R. P. Ekanayaka, W. M. Tilakaratne Oral Diseases.2024;[Epub] CrossRef
Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma James C. H. Chow, Wah Cheuk, William C. S. Cho, Chi-Fai Wong, Dennis W. Y. Au, Anthony H. P. Tam, Rachel C. W. Wong, Jeffrey C. H. Chan, Simon C. C. Law, Roger K. C. Ngan, Kam-Hung Wong, Ka-Man Cheung JAMA Network Open.2023; 6(7): e2323890. CrossRef
Clinical characterization of radiation-associated muscle-invasive bladder cancer Sybil T. Sha, Edward Christopher Dee, Matthew Mossanen, Brandon A. Mahal, Cierra Zaslowe-Dude, Trevor J. Royce, Michelle S. Hirsch, Guru Sonpavde, Mark A. Preston, Paul L. Nguyen, Kent W. Mouw, Vinayak Muralidhar Urology.2021; 154: 208. CrossRef
SPP1 and FN1 are significant gene biomarkers of tongue squamous cell carcinoma Xiao-Liang Xu, Hui Liu, Ying Zhang, Su-Xin Zhang, Zhong Chen, Yang Bao, Tian-Ke Li Oncology Letters.2021;[Epub] CrossRef
Secondary Squamous Cell Carcinoma of the Oral Cavity after Nasopharyngeal Carcinoma Liyuan Dai, Qigen Fang, Peng Li, Junfu Wu, Xu Zhang Cancer Research and Treatment.2020; 52(1): 109. CrossRef
Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG James C.H. Chow, Anthony H.P. Tam, Ka-Man Cheung, Victor H.F. Lee, Chi-Leung Chiang, Macy Tong, Edwin C.Y. Wong, Alice K.W. Cheung, Sunny P.C. Chan, Jessica W.Y. Lai, Roger K.C. Ngan, Wai-Tong Ng, Anne W.M. Lee, Kwok-Hung Au Oral Oncology.2020; 111: 105012. CrossRef
BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma Miao Wang, Lu Zhao, Dongdong Tong, Linrui Yang, Hongjie Zhu, Qing Li, Fenghe Zhang International Immunopharmacology.2019; 76: 105921. CrossRef
Surgical treatment of early tongue squamous cell carcinoma and patient survival Lansheng Zhu, Yanling Wang, Rui Li, Aiqun Liu, Xiaoping Zhang, Chunran Zuo, Xiaoting Xu Oncology Letters.2019;[Epub] CrossRef
Keratin 6A gene silencing suppresses cell invasion and metastasis of nasopharyngeal carcinoma via the β‑catenin cascade Chuanjun Chen, Huiguo Shan Molecular Medicine Reports.2019;[Epub] CrossRef
Tumour budding in oral squamous cell carcinoma: a meta-analysis Alhadi Almangush, Matti Pirinen, Ilkka Heikkinen, Antti A Mäkitie, Tuula Salo, Ilmo Leivo British Journal of Cancer.2018; 118(4): 577. CrossRef
The poor outcome of second primary oral squamous cell carcinoma is attributed to Bmi1 upregulation Qinchao Hu, Tong Wu, Xiaobing Chen, Huan Li, Zhicheng Du, Yuantao Hao, Jianmin Peng, Shanshan Tai, Ming Song, Bin Cheng Cancer Medicine.2018; 7(4): 1056. CrossRef
Clinical analysis of second primary gingival squamous cell carcinoma after radiotherapy Xiaoyan Fu, Shuwei Chen, Weichao Chen, Zhongyuan Yang, Ming Song, Hao Li, Huayong Zhang, Fan Yao, Xuan Su, Tianrun Liu, An-Kui Yang Oral Oncology.2018; 84: 20. CrossRef
PURPOSE The current study was conducted in order to evaluate the clinical outcome of radical radiotherapy (RT) with or without chemotherapy for elderly patients with stage III non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Between 1990 and 2010, 125 patients, aged 70 years or more, received radical RT with or without chemotherapy for treatment of stage III NSCLC. We reviewed the patients' prognostic factors, including comorbidities.
Comorbidity status was evaluated using a simplified comorbidity score (SCS). Of the patients reviewed, 82 received radical RT alone, whereas the other 43 patients underwent chemoradiotherapy (CRT). A platinum-based chemotherapy regimen was most commonly used (42/43). RESULTS The two-year overall-survival (OS) and progression-free survival (PFS) rates were 32.2% and 21.8%, respectively. SCS was the independent prognostic factor for OS. In the frail elderly subgroup with a SCS of > or =10, CRT demonstrated a significant difference in PFS, but not in OS. In contrast, OS and PFS following CRT were significantly superior to RT in the fit elderly subgroup with a SCS of <10. The incidence of severe pulmonary toxicities in the frail elderly subgroup was significantly higher than that in the fit elderly subgroup. CONCLUSION Multiple comorbidities evaluated according to the SCS are related to poor OS in elderly patients with stage III NSCLC. CRT improved clinical outcome when compared to RT in the fit elderly subgroup, however, the gain from this treatment was negated in the frail elderly subgroup with multiple comorbidities. Therefore, evaluation of comorbidity is necessary in order to determine whether chemotherapy should be combined with RT in elderly patients with stage III NSCLC.
Citations
Citations to this article as recorded by
Clinicopathological characteristics and prognosis of non-small cell lung cancer in Algeria: a single-center retrospective study Mohamed Lahmadi, Leila Beddar, Souad Ketit, Tarek Makhbouche, Narriman Laouar, Taha Filali BMC Cancer.2024;[Epub] CrossRef
Considerations of Medical Preparedness to Assess and Treat Various Populations During a Radiation Public Health Emergency Thomas A. Winters, David R. Cassatt, Jenna R. Harrison-Peters, Brynn A. Hollingsworth, Carmen I. Rios, Merriline M. Satyamitra, Lanyn P. Taliaferro, Andrea L. DiCarlo Radiation Research.2023;[Epub] CrossRef
Independent Predictors for Hospitalization-Associated Radiation therapy Interruptions Adam Hubler, Daniel V. Wakefield, Lydia Makepeace, Matt Carnell, Ankur M. Sharma, Bo Jiang, Austin P. Dove, Wesley B. Garner, Drucilla Edmonston, John G. Little, Esra Ozdenerol, Ryan B. Hanson, Michelle Y. Martin, Arash Shaban-Nejad, Maria Pisu, David L. Advances in Radiation Oncology.2022; 7(6): 101041. CrossRef
Behandlung des Analkarzinoms Natalie Schindler, Irenäus A. Adamietz Der Onkologe.2021; 27(6): 615. CrossRef
Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy Magdalena Zaborowska-Szmit, Marta Olszyna-Serementa, Dariusz M. Kowalski, Sebastian Szmit, Maciej Krzakowski Cancers.2021; 13(18): 4534. CrossRef
Cancer incidence and survival analysis among elderly people in Bingol province Burak METE, Vedat SÖYİLER, Bilal BUZGAN Cukurova Medical Journal.2020; 45(1): 290. CrossRef
Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer Navneet Singh, Potsangbam Sarat Singh, Ashutosh N. Aggarwal, Digambar Behera Clinical Lung Cancer.2016; 17(3): 205. CrossRef
A review of the management of elderly patients with non-small-cell lung cancer R. Blanco, I. Maestu, M.G. de la Torre, A. Cassinello, I. Nuñez Annals of Oncology.2015; 26(3): 451. CrossRef
Age dependent prognosis in concurrent chemo-radiation of locally advanced NSCLC Olfred Hansen, Tine Schytte, Morten Nielsen, Carsten Brink Acta Oncologica.2015; 54(3): 333. CrossRef
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial Hans H. Strøm, Roy M. Bremnes, Stein H. Sundstrøm, Nina Helbekkmo, Ulf Aasebø Clinical Lung Cancer.2015; 16(3): 183. CrossRef
Therapie des Analkarzinoms I. Fraunholz, G. Woeste, R.-D. Hofheinz Der Onkologe.2014; 20(2): 173. CrossRef
Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010 Ellen J. F. van Reij, Max Dahele, Peter M. van de Ven, Patricia F. de Haan, Wilko F. A. R. Verbakel, Egbert F. Smit, Ben J. Slotman, Suresh Senan Acta Oncologica.2014; 53(3): 316. CrossRef
The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients Jeong Won Lee, Jong Hoon Lee, Hoon-Kyo Kim, Byoung Yong Shim, Ho Jung An, Sung Hwan Kim Cancer Research and Treatment.2014; 47(2): 189. CrossRef
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer Mun Sem Liew, Joseph Sia, Maud H. W. Starmans, Ali Tafreshi, Sam Harris, Malcolm Feigen, Shane White, Allan Zimet, Philippe Lambin, Paul C. Boutros, Paul Mitchell, Thomas John Cancer Medicine.2013; 2(6): 916. CrossRef
Strahlentherapie im Alter A.-L. Grosu, K. Henne Forum.2013; 28(3): 170. CrossRef
PURPOSE The purpose of this study was to test the hypothesis that neoadjuvant chemotherapy (NACT) does not increase morbidity in patients undergoing radical hysterectomy with lymphadenectomy for locally advanced cervical cancer.
MATERIALS AND METGODS: A retrospective study was undertaken of 140 patients with locally advanced cervical cancer (FIGO stage Ia to IIb) who underwent radical hysterectomy with lymphadenectomy by the same surgeon at the same hospital.
Among the 140 patients, 39 received NACT followed by radical hysterectomy with pelvic lymphadenectomy (NACT group). This group received three cycles consisting of cisplatin 100 mg/m2/day on day 1 and 5-fluorouracil 1000 mg/m2/day from day 1 to 5. The NACT group was compared, in terms of intraoperative morbidity and postoperative morbidity, with the other 101 patients who underwent radical hysterectomy with lymphadenectomy but without chemotherapy (surgery-only group). RESULTS There were no significant differences in mean age, body weight or height between the two groups. The only significant difference was that the NACT patients had higher stages of cancer. The incidence of intraoperative morbidity did not differ between the NACT and surgery only patients.
We considered the operation duration, amount of blood loss and need for transfusion as indicators of intraoperative morbidity. We could not find any significant differences in the duration of suprapubic catheterization, days of hemovac drainage, amount of drained hemovac fluid, days of hospitalization or postoperative febrile morbidity between the NACT and surgery-only groups. Patients in the surgery-only group had more postoperative complications (ureteral obstruction, intestinal obstruction, lymphocyst, lymphedema, and death) than the NACT group, although not to a statistically significant degree (P>0.05). CONCLUSION In this retrospective review, there was no evidence that NACT increased intraoperative or postoperative morbidity in patients with locally advanced cervical cancer.
As this was a retrospective study, other prospective, randomized studies are needed to confirm these results.
Citations
Citations to this article as recorded by
The Role of 2D/3D Ultrasound to Assess the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Giorgia Perniola, Federica Tomao, Marialida Graziano, Innocenza Palaia, Margherita Fischetti, Francesca Lecce, Assunta Casorelli, Violante Di Donato, Antonella Giancotti, Francesco Antonio Battaglia, Ludovico Muzii, Pierluigi Benedetti Panici Oncology.2020; 98(11): 807. CrossRef